Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($)
$ in Millions |
12 Months Ended |
|
|
Jan. 03, 2021 |
Dec. 29, 2019 |
Dec. 30, 2018 |
Oct. 31, 2020 |
Oct. 31, 2019 |
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 82,584
|
$ 82,059
|
$ 81,581
|
|
|
| Percentage Change In Sales By Segment Of Business |
0.60%
|
0.60%
|
|
|
|
| Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 14,053
|
$ 13,898
|
13,853
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.10%
|
0.30%
|
|
|
|
| Pharmaceutical |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 45,572
|
$ 42,198
|
40,734
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.00%
|
3.60%
|
|
|
|
| Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 15,055
|
$ 13,950
|
13,120
|
|
|
| Percentage Change In Sales By Segment Of Business |
7.90%
|
6.30%
|
|
|
|
| Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,574
|
$ 3,413
|
3,304
|
|
|
| Percentage Change In Sales By Segment Of Business |
4.70%
|
3.30%
|
|
|
|
| Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 6,548
|
$ 6,328
|
6,077
|
|
|
| Percentage Change In Sales By Segment Of Business |
3.50%
|
4.10%
|
|
|
|
| Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 12,367
|
$ 10,692
|
9,844
|
|
|
| Percentage Change In Sales By Segment Of Business |
15.70%
|
8.60%
|
|
|
|
| Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,148
|
$ 2,623
|
2,573
|
|
|
| Percentage Change In Sales By Segment Of Business |
20.00%
|
1.90%
|
|
|
|
| Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,878
|
$ 5,192
|
5,816
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.00%)
|
(10.70%)
|
|
|
|
| Medical Devices |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 22,959
|
$ 25,963
|
26,994
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.60%)
|
(3.80%)
|
|
|
|
| Medical Devices | Diabetes Care |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
|
|
1,009
|
|
|
| Medical Devices | Interventional Solutions |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,046
|
$ 2,997
|
2,646
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.60%
|
13.30%
|
|
|
|
| Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 7,763
|
$ 8,839
|
8,885
|
|
|
| Percentage Change In Sales By Segment Of Business |
(12.20%)
|
(0.50%)
|
|
|
|
| Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 8,232
|
$ 9,501
|
9,901
|
|
|
| Percentage Change In Sales By Segment Of Business |
(13.40%)
|
(4.00%)
|
|
|
|
| Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,919
|
$ 4,624
|
4,553
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.20%)
|
1.60%
|
|
|
|
| Baby Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,517
|
$ 1,675
|
1,858
|
|
|
| Percentage Change In Sales By Segment Of Business |
(9.40%)
|
(9.90%)
|
|
|
|
| Oral Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,641
|
$ 1,528
|
1,555
|
|
|
| Percentage Change In Sales By Segment Of Business |
7.40%
|
(1.70%)
|
|
|
|
| OTC | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,824
|
$ 4,444
|
4,334
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.50%
|
2.50%
|
|
|
|
| Women's Health | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 901
|
$ 986
|
1,049
|
|
|
| Percentage Change In Sales By Segment Of Business |
(8.60%)
|
(6.00%)
|
|
|
|
| Wound Care and Other | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 720
|
$ 671
|
675
|
|
|
| Percentage Change In Sales By Segment Of Business |
7.20%
|
(0.60%)
|
|
|
|
| Remicade | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,747
|
$ 4,380
|
5,326
|
|
|
| Percentage Change In Sales By Segment Of Business |
(14.40%)
|
(17.80%)
|
|
|
|
| Simponi/Simponi Aria | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,243
|
$ 2,188
|
2,084
|
|
|
| Percentage Change In Sales By Segment Of Business |
2.60%
|
5.00%
|
|
|
|
| Stelara | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 7,707
|
$ 6,361
|
5,156
|
|
|
| Percentage Change In Sales By Segment Of Business |
21.10%
|
23.40%
|
|
|
|
| Tremfya | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,347
|
$ 1,012
|
544
|
|
|
| Percentage Change In Sales By Segment Of Business |
33.20%
|
85.90%
|
|
|
|
| Other Immunology | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 11
|
$ 10
|
10
|
|
|
| Percentage Change In Sales By Segment Of Business |
6.40%
|
4.50%
|
|
|
|
| EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 964
|
$ 861
|
816
|
|
|
| Percentage Change In Sales By Segment Of Business |
11.90%
|
5.60%
|
|
|
|
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,184
|
$ 2,110
|
1,955
|
|
|
| Percentage Change In Sales By Segment Of Business |
3.50%
|
8.00%
|
|
|
|
| Other Infectious Diseases | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 427
|
$ 441
|
533
|
|
|
| Percentage Change In Sales By Segment Of Business |
(3.20%)
|
(17.30%)
|
|
|
|
| CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 622
|
$ 696
|
663
|
|
|
| Percentage Change In Sales By Segment Of Business |
(10.60%)
|
4.90%
|
|
|
|
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,653
|
$ 3,330
|
2,928
|
|
|
| Percentage Change In Sales By Segment Of Business |
9.70%
|
13.70%
|
|
|
|
| RISPERDAL CONSTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 642
|
$ 688
|
737
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.80%)
|
(6.70%)
|
|
|
|
| OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,632
|
$ 1,614
|
1,749
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.10%
|
(7.70%)
|
|
|
|
| DARZALEX | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,190
|
$ 2,998
|
2,025
|
|
|
| Percentage Change In Sales By Segment Of Business |
39.80%
|
48.00%
|
|
|
|
| Erleada | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 760
|
$ 332
|
124
|
|
|
| IMBRUVICA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,128
|
$ 3,411
|
2,615
|
|
|
| Percentage Change In Sales By Segment Of Business |
21.00%
|
30.40%
|
|
|
|
| VELCADE | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 408
|
$ 751
|
1,116
|
|
|
| Percentage Change In Sales By Segment Of Business |
(45.70%)
|
(32.70%)
|
|
|
|
| ZYTIGA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,470
|
$ 2,795
|
3,498
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.60%)
|
(20.10%)
|
|
|
|
| Other Oncology | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 413
|
$ 407
|
466
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.70%
|
(12.70%)
|
|
|
|
| OPSUMIT | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,639
|
$ 1,327
|
1,215
|
|
|
| Percentage Change In Sales By Segment Of Business |
23.50%
|
9.20%
|
|
|
|
| UPTRAVI | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,093
|
$ 819
|
663
|
|
|
| Percentage Change In Sales By Segment Of Business |
33.50%
|
23.50%
|
|
|
|
| Other | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 416
|
$ 476
|
695
|
|
|
| Percentage Change In Sales By Segment Of Business |
(12.80%)
|
(31.50%)
|
|
|
|
| Other | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,186
|
$ 1,353
|
1,470
|
|
|
| Percentage Change In Sales By Segment Of Business |
(12.40%)
|
(8.00%)
|
|
|
|
| Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,345
|
$ 2,313
|
2,477
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.40%
|
(6.60%)
|
|
|
|
| INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 795
|
$ 735
|
881
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.20%
|
(16.50%)
|
|
|
|
| PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 552
|
$ 790
|
988
|
|
|
| Percentage Change In Sales By Segment Of Business |
(30.20%)
|
(20.00%)
|
|
|
|
| HIPS | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,280
|
$ 1,438
|
1,418
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.00%)
|
1.40%
|
|
|
|
| KNEES | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,170
|
$ 1,480
|
1,502
|
|
|
| Percentage Change In Sales By Segment Of Business |
(21.00%)
|
(1.40%)
|
|
|
|
| TRAUMA | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,614
|
$ 2,720
|
2,699
|
|
|
| Percentage Change In Sales By Segment Of Business |
(3.90%)
|
0.80%
|
|
|
|
| SPINE & OTHER | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,699
|
$ 3,201
|
3,266
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.70%)
|
(2.00%)
|
|
|
|
| ADVANCED | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,839
|
$ 4,095
|
4,002
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.20%)
|
2.30%
|
|
|
|
| GENERAL | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,392
|
$ 5,406
|
5,899
|
|
|
| Percentage Change In Sales By Segment Of Business |
(18.80%)
|
(8.40%)
|
|
|
|
| CONTACT LENSES/OTHER | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,994
|
$ 3,392
|
3,302
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.70%)
|
2.70%
|
|
|
|
| SURGICAL | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 925
|
$ 1,232
|
1,251
|
|
|
| Percentage Change In Sales By Segment Of Business |
(24.90%)
|
(1.60%)
|
|
|
|
| Skin health/Beauty | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,450
|
$ 4,593
|
4,382
|
|
|
| Percentage Change In Sales By Segment Of Business |
(3.10%)
|
4.80%
|
|
|
|
| United States |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 43,133
|
$ 42,097
|
41,884
|
|
|
| Percentage Change In Sales By Segment Of Business |
2.50%
|
0.50%
|
|
|
|
| United States | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 6,362
|
$ 5,839
|
5,761
|
|
|
| Percentage Change In Sales By Segment Of Business |
9.00%
|
1.40%
|
|
|
|
| United States | Pharmaceutical |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 25,735
|
$ 23,874
|
23,286
|
|
|
| Percentage Change In Sales By Segment Of Business |
7.80%
|
2.50%
|
|
|
|
| United States | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 10,175
|
$ 9,641
|
9,073
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.50%
|
6.30%
|
|
|
|
| United States | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,735
|
$ 1,597
|
1,378
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.60%
|
15.90%
|
|
|
|
| United States | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,091
|
$ 2,919
|
2,574
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.90%
|
13.40%
|
|
|
|
| United States | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 5,092
|
$ 4,299
|
4,331
|
|
|
| Percentage Change In Sales By Segment Of Business |
18.50%
|
(0.70%)
|
|
|
|
| United States | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,133
|
$ 1,684
|
1,651
|
|
|
| Percentage Change In Sales By Segment Of Business |
26.60%
|
2.00%
|
|
|
|
| United States | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,509
|
$ 3,734
|
4,279
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.00%)
|
(12.70%)
|
|
|
|
| United States | Pharmaceutical | OPSUMIT |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Percentage Change In Sales By Segment Of Business |
|
9.40%
|
|
|
|
| United States | Medical Devices |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 11,036
|
$ 12,384
|
12,837
|
|
|
| Percentage Change In Sales By Segment Of Business |
(10.90%)
|
(3.50%)
|
|
|
|
| United States | Medical Devices | Diabetes Care |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
|
|
371
|
|
|
| United States | Medical Devices | Interventional Solutions |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,452
|
$ 1,443
|
1,283
|
|
|
| Percentage Change In Sales By Segment Of Business |
0.60%
|
12.50%
|
|
|
|
| United States | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,779
|
$ 5,319
|
5,281
|
|
|
| Percentage Change In Sales By Segment Of Business |
(10.20%)
|
0.70%
|
|
|
|
| United States | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,249
|
$ 3,828
|
4,125
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.10%)
|
(7.20%)
|
|
|
|
| United States | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,557
|
$ 1,794
|
1,777
|
|
|
| Percentage Change In Sales By Segment Of Business |
(13.20%)
|
0.90%
|
|
|
|
| United States | Baby Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 376
|
$ 362
|
422
|
|
|
| Percentage Change In Sales By Segment Of Business |
3.70%
|
(14.20%)
|
|
|
|
| United States | Oral Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 683
|
$ 621
|
637
|
|
|
| Percentage Change In Sales By Segment Of Business |
9.90%
|
(2.50%)
|
|
|
|
| United States | OTC | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,460
|
$ 2,010
|
1,850
|
|
|
| Percentage Change In Sales By Segment Of Business |
22.40%
|
8.60%
|
|
|
|
| United States | Women's Health | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 13
|
$ 12
|
13
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.20%
|
(5.50%)
|
|
|
|
| United States | Wound Care and Other | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 480
|
$ 441
|
436
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.90%
|
1.20%
|
|
|
|
| United States | Remicade | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,508
|
$ 3,079
|
3,664
|
|
|
| Percentage Change In Sales By Segment Of Business |
(18.50%)
|
(16.00%)
|
|
|
|
| United States | Simponi/Simponi Aria | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,155
|
$ 1,159
|
1,051
|
|
|
| Percentage Change In Sales By Segment Of Business |
(0.30%)
|
10.20%
|
|
|
|
| United States | Stelara | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 5,240
|
$ 4,346
|
3,469
|
|
|
| Percentage Change In Sales By Segment Of Business |
20.60%
|
25.30%
|
|
|
|
| United States | Tremfya | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 926
|
$ 764
|
453
|
|
|
| Percentage Change In Sales By Segment Of Business |
21.30%
|
68.50%
|
|
|
|
| United States | Other Immunology | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 0
|
$ 0
|
0
|
|
|
| Percentage Change In Sales By Segment Of Business |
0.00%
|
0.00%
|
|
|
|
| United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 44
|
$ 50
|
58
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.20%)
|
(13.70%)
|
|
|
|
| United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,587
|
$ 1,422
|
1,169
|
|
|
| Percentage Change In Sales By Segment Of Business |
11.60%
|
21.60%
|
|
|
|
| United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 104
|
$ 126
|
151
|
|
|
| Percentage Change In Sales By Segment Of Business |
(17.60%)
|
(16.50%)
|
|
|
|
| United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 183
|
$ 233
|
229
|
|
|
| Percentage Change In Sales By Segment Of Business |
(21.40%)
|
1.70%
|
|
|
|
| United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,314
|
$ 2,107
|
1,791
|
|
|
| Percentage Change In Sales By Segment Of Business |
9.80%
|
17.60%
|
|
|
|
| United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 296
|
$ 314
|
315
|
|
|
| Percentage Change In Sales By Segment Of Business |
(5.90%)
|
(0.30%)
|
|
|
|
| United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 298
|
$ 266
|
239
|
|
|
| Percentage Change In Sales By Segment Of Business |
12.40%
|
11.40%
|
|
|
|
| United States | DARZALEX | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,232
|
$ 1,567
|
1,203
|
|
|
| Percentage Change In Sales By Segment Of Business |
42.40%
|
30.30%
|
|
|
|
| United States | Erleada | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 583
|
$ 297
|
124
|
|
|
| Percentage Change In Sales By Segment Of Business |
96.10%
|
|
|
|
|
| United States | IMBRUVICA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,821
|
$ 1,555
|
1,129
|
|
|
| Percentage Change In Sales By Segment Of Business |
17.10%
|
37.70%
|
|
|
|
| United States | VELCADE | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 0
|
$ 0
|
0
|
|
|
| Percentage Change In Sales By Segment Of Business |
0.00%
|
0.00%
|
|
|
|
| United States | ZYTIGA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 373
|
$ 810
|
1,771
|
|
|
| Percentage Change In Sales By Segment Of Business |
(54.00%)
|
(54.30%)
|
|
|
|
| United States | Other Oncology | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 83
|
$ 70
|
104
|
|
|
| Percentage Change In Sales By Segment Of Business |
19.20%
|
(32.70%)
|
|
|
|
| United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,008
|
$ 766
|
700
|
|
|
| Percentage Change In Sales By Segment Of Business |
31.70%
|
|
|
|
|
| United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 955
|
$ 714
|
598
|
|
|
| Percentage Change In Sales By Segment Of Business |
33.80%
|
19.30%
|
|
|
|
| United States | Other | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 169
|
$ 205
|
353
|
|
|
| Percentage Change In Sales By Segment Of Business |
(17.60%)
|
(41.90%)
|
|
|
|
| United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 323
|
$ 380
|
417
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.10%)
|
(9.10%)
|
|
|
|
| United States | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,345
|
$ 2,313
|
2,477
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.40%
|
(6.60%)
|
|
|
|
| United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 564
|
$ 536
|
711
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.20%
|
(24.60%)
|
|
|
|
| United States | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 277
|
$ 505
|
674
|
|
|
| Percentage Change In Sales By Segment Of Business |
(45.10%)
|
(25.10%)
|
|
|
|
| United States | HIPS | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 793
|
$ 863
|
841
|
|
|
| Percentage Change In Sales By Segment Of Business |
(8.20%)
|
2.60%
|
|
|
|
| United States | KNEES | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 743
|
$ 889
|
911
|
|
|
| Percentage Change In Sales By Segment Of Business |
(16.40%)
|
(2.40%)
|
|
|
|
| United States | TRAUMA | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,648
|
$ 1,652
|
1,599
|
|
|
| Percentage Change In Sales By Segment Of Business |
(0.20%)
|
3.30%
|
|
|
|
| United States | SPINE & OTHER | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,595
|
$ 1,915
|
1,930
|
|
|
| Percentage Change In Sales By Segment Of Business |
(16.70%)
|
(0.80%)
|
|
|
|
| United States | ADVANCED | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,535
|
$ 1,637
|
1,657
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.20%)
|
(1.20%)
|
|
|
|
| United States | GENERAL | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,714
|
$ 2,192
|
2,468
|
|
|
| Percentage Change In Sales By Segment Of Business |
(21.80%)
|
(11.20%)
|
|
|
|
| United States | CONTACT LENSES/OTHER | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,213
|
$ 1,304
|
1,237
|
|
|
| Percentage Change In Sales By Segment Of Business |
(7.00%)
|
5.40%
|
|
|
|
| United States | SURGICAL | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 344
|
$ 490
|
540
|
|
|
| Percentage Change In Sales By Segment Of Business |
(29.70%)
|
(9.40%)
|
|
|
|
| United States | Skin health/Beauty | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,350
|
$ 2,392
|
2,403
|
|
|
| Percentage Change In Sales By Segment Of Business |
(1.70%)
|
(0.40%)
|
|
|
|
| Non-US |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 39,451
|
$ 39,962
|
39,697
|
|
|
| Percentage Change In Sales By Segment Of Business |
(1.30%)
|
0.70%
|
|
|
|
| Non-US | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 7,691
|
$ 8,059
|
8,092
|
|
|
| Percentage Change In Sales By Segment Of Business |
(4.60%)
|
(0.40%)
|
|
|
|
| Non-US | Pharmaceutical |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 19,837
|
$ 18,324
|
17,448
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.30%
|
5.00%
|
|
|
|
| Non-US | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,880
|
$ 4,309
|
4,047
|
|
|
| Percentage Change In Sales By Segment Of Business |
13.20%
|
6.50%
|
|
|
|
| Non-US | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,839
|
$ 1,815
|
1,926
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.30%
|
(5.70%)
|
|
|
|
| Non-US | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 3,457
|
$ 3,409
|
3,503
|
|
|
| Percentage Change In Sales By Segment Of Business |
1.40%
|
(2.70%)
|
|
|
|
| Non-US | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 7,275
|
$ 6,393
|
5,513
|
|
|
| Percentage Change In Sales By Segment Of Business |
13.80%
|
16.00%
|
|
|
|
| Non-US | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,015
|
$ 939
|
922
|
|
|
| Percentage Change In Sales By Segment Of Business |
8.20%
|
1.90%
|
|
|
|
| Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,369
|
$ 1,458
|
1,537
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.10%)
|
(5.20%)
|
|
|
|
| Non-US | Pharmaceutical | OPSUMIT |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Percentage Change In Sales By Segment Of Business |
|
9.00%
|
|
|
|
| Non-US | Medical Devices |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 11,923
|
$ 13,579
|
14,157
|
|
|
| Percentage Change In Sales By Segment Of Business |
(12.20%)
|
(4.10%)
|
|
|
|
| Non-US | Medical Devices | Diabetes Care |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
|
|
638
|
|
|
| Non-US | Medical Devices | Interventional Solutions |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,594
|
$ 1,554
|
1,363
|
|
|
| Percentage Change In Sales By Segment Of Business |
2.60%
|
14.00%
|
|
|
|
| Non-US | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,984
|
$ 3,520
|
3,604
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.20%)
|
(2.30%)
|
|
|
|
| Non-US | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 4,983
|
$ 5,673
|
5,776
|
|
|
| Percentage Change In Sales By Segment Of Business |
(12.20%)
|
(1.80%)
|
|
|
|
| Non-US | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,362
|
$ 2,830
|
2,776
|
|
|
| Percentage Change In Sales By Segment Of Business |
(16.50%)
|
2.00%
|
|
|
|
| Non-US | Baby Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,141
|
$ 1,313
|
1,436
|
|
|
| Percentage Change In Sales By Segment Of Business |
(13.10%)
|
(8.60%)
|
|
|
|
| Non-US | Oral Care | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 958
|
$ 906
|
918
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.70%
|
(1.20%)
|
|
|
|
| Non-US | OTC | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,364
|
$ 2,434
|
2,484
|
|
|
| Percentage Change In Sales By Segment Of Business |
(2.90%)
|
(2.00%)
|
|
|
|
| Non-US | Women's Health | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 888
|
$ 974
|
1,036
|
|
|
| Percentage Change In Sales By Segment Of Business |
(8.80%)
|
(6.00%)
|
|
|
|
| Non-US | Wound Care and Other | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 240
|
$ 230
|
239
|
|
|
| Percentage Change In Sales By Segment Of Business |
4.10%
|
(3.90%)
|
|
|
|
| Non-US | Remicade | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 893
|
$ 1,007
|
1,226
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.40%)
|
(17.80%)
|
|
|
|
| Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,088
|
$ 1,029
|
1,033
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.80%
|
(0.40%)
|
|
|
|
| Non-US | Stelara | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,467
|
$ 2,015
|
1,687
|
|
|
| Percentage Change In Sales By Segment Of Business |
22.40%
|
19.40%
|
|
|
|
| Non-US | Tremfya | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 421
|
$ 248
|
91
|
|
|
| Percentage Change In Sales By Segment Of Business |
69.90%
|
|
|
|
|
| Non-US | Other Immunology | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 11
|
$ 10
|
10
|
|
|
| Percentage Change In Sales By Segment Of Business |
6.40%
|
4.50%
|
|
|
|
| Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 920
|
$ 812
|
758
|
|
|
| Percentage Change In Sales By Segment Of Business |
13.30%
|
7.10%
|
|
|
|
| Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 597
|
$ 689
|
786
|
|
|
| Percentage Change In Sales By Segment Of Business |
(13.40%)
|
(12.30%)
|
|
|
|
| Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 323
|
$ 315
|
382
|
|
|
| Percentage Change In Sales By Segment Of Business |
2.60%
|
(17.60%)
|
|
|
|
| Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 439
|
$ 463
|
434
|
|
|
| Percentage Change In Sales By Segment Of Business |
(5.10%)
|
6.60%
|
|
|
|
| Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,339
|
$ 1,224
|
1,137
|
|
|
| Percentage Change In Sales By Segment Of Business |
9.40%
|
7.70%
|
|
|
|
| Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 346
|
$ 374
|
422
|
|
|
| Percentage Change In Sales By Segment Of Business |
(7.50%)
|
(11.40%)
|
|
|
|
| Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,334
|
$ 1,349
|
1,510
|
|
|
| Percentage Change In Sales By Segment Of Business |
(1.10%)
|
(10.70%)
|
|
|
|
| Non-US | DARZALEX | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,958
|
$ 1,430
|
822
|
|
|
| Percentage Change In Sales By Segment Of Business |
36.90%
|
73.90%
|
|
|
|
| Non-US | Erleada | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 176
|
$ 35
|
0
|
|
|
| Non-US | IMBRUVICA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,307
|
$ 1,856
|
1,486
|
|
|
| Percentage Change In Sales By Segment Of Business |
24.30%
|
24.90%
|
|
|
|
| Non-US | VELCADE | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 408
|
$ 751
|
1,116
|
|
|
| Percentage Change In Sales By Segment Of Business |
(45.70%)
|
(32.70%)
|
|
|
|
| Non-US | ZYTIGA | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,097
|
$ 1,985
|
1,727
|
|
|
| Percentage Change In Sales By Segment Of Business |
5.60%
|
15.00%
|
|
|
|
| Non-US | Other Oncology | Pharmaceutical | Oncology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 330
|
$ 336
|
362
|
|
|
| Percentage Change In Sales By Segment Of Business |
(1.90%)
|
(7.20%)
|
|
|
|
| Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 631
|
$ 562
|
515
|
|
|
| Percentage Change In Sales By Segment Of Business |
12.30%
|
|
|
|
|
| Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 138
|
$ 105
|
65
|
|
|
| Percentage Change In Sales By Segment Of Business |
30.90%
|
62.40%
|
|
|
|
| Non-US | Other | Pharmaceutical | Pulmonary Hypertension |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 247
|
$ 272
|
342
|
|
|
| Percentage Change In Sales By Segment Of Business |
(9.20%)
|
(20.50%)
|
|
|
|
| Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 864
|
$ 974
|
1,053
|
|
|
| Percentage Change In Sales By Segment Of Business |
(11.30%)
|
(7.60%)
|
|
|
|
| Non-US | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 0
|
$ 0
|
0
|
|
|
| Percentage Change In Sales By Segment Of Business |
0.00%
|
0.00%
|
|
|
|
| Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 231
|
$ 199
|
170
|
|
|
| Percentage Change In Sales By Segment Of Business |
16.30%
|
17.30%
|
|
|
|
| Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 274
|
$ 285
|
314
|
|
|
| Percentage Change In Sales By Segment Of Business |
(3.80%)
|
(9.20%)
|
|
|
|
| Non-US | HIPS | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 487
|
$ 575
|
577
|
|
|
| Percentage Change In Sales By Segment Of Business |
(15.30%)
|
(0.30%)
|
|
|
|
| Non-US | KNEES | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 427
|
$ 591
|
591
|
|
|
| Percentage Change In Sales By Segment Of Business |
(27.80%)
|
0.00%
|
|
|
|
| Non-US | TRAUMA | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 966
|
$ 1,068
|
1,100
|
|
|
| Percentage Change In Sales By Segment Of Business |
(9.60%)
|
(2.90%)
|
|
|
|
| Non-US | SPINE & OTHER | Medical Devices | Orthopaedics |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,104
|
$ 1,286
|
1,336
|
|
|
| Percentage Change In Sales By Segment Of Business |
(14.10%)
|
(3.80%)
|
|
|
|
| Non-US | ADVANCED | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,304
|
$ 2,458
|
2,345
|
|
|
| Percentage Change In Sales By Segment Of Business |
(6.20%)
|
4.80%
|
|
|
|
| Non-US | GENERAL | Medical Devices | Surgery |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,679
|
$ 3,215
|
3,431
|
|
|
| Percentage Change In Sales By Segment Of Business |
(16.70%)
|
(6.30%)
|
|
|
|
| Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 1,781
|
$ 2,088
|
2,065
|
|
|
| Percentage Change In Sales By Segment Of Business |
(14.70%)
|
1.10%
|
|
|
|
| Non-US | SURGICAL | Medical Devices | Vision |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 581
|
$ 742
|
711
|
|
|
| Percentage Change In Sales By Segment Of Business |
(21.70%)
|
4.40%
|
|
|
|
| Non-US | Skin health/Beauty | Consumer |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 2,100
|
$ 2,201
|
1,979
|
|
|
| Percentage Change In Sales By Segment Of Business |
(4.60%)
|
11.20%
|
|
|
|
| UNITED STATES Exports | Remicade | Pharmaceutical | Immunology |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Sales to Customers |
$ 346
|
$ 294
|
$ 436
|
|
|
| Percentage Change In Sales By Segment Of Business |
18.00%
|
(32.70%)
|
|
|
|
| Auris Health | Pharmaceutical |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Business Combination, Acquisition Related Costs |
|
$ 100
|
|
|
|
| Pending Litigation |
|
|
|
|
|
| Segment Reporting Information [Line Items] |
|
|
|
|
|
| Loss contingency, estimate of possible loss |
|
|
|
$ 5,000
|
$ 4,000
|